Get Mounjaro® (tirzepatide) prescribed online by licensed physicians. Mounjaro is the first dual GIP/GLP-1 injection FDA-approved for type 2 diabetes — delivering some of the strongest blood-sugar control of any GLP-1 medication. Telehealth visit, shipped to your door.
Mounjaro® is the brand name for tirzepatide, a once-weekly injectable medication from Eli Lilly that the FDA approved in 2022 to improve blood-sugar control in adults with type 2 diabetes. It was the first medication of its kind: a dual agonist that activates two natural gut hormones — GIP and GLP-1 — rather than just one. That dual action is why tirzepatide has produced some of the largest A1C reductions of any diabetes medication in head-to-head clinical trials.
With a telehealth visit, you can get a Mounjaro prescription online without an in-person appointment. A licensed physician reviews your medical history, confirms whether Mounjaro is appropriate for your diagnosis, and — if it is — sends your prescription to a licensed pharmacy that ships the medication to your door, with ongoing dose and side-effect support included.
Mounjaro and Zepbound® contain the same active ingredient, tirzepatide, but they are approved for different uses: Mounjaro for type 2 diabetes and Zepbound for chronic weight management. If your primary goal is weight loss, Zepbound is the FDA-approved option — and our physicians can help you choose. You can also compare Mounjaro with Ozempic® (semaglutide) further down this page.
Once-weekly injectable · FDA-approved for type 2 diabetes
Mounjaro® (tirzepatide) is a once-weekly injection from Eli Lilly, FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults and children 10 and older with type 2 diabetes. It is the first-in-class dual agonist — it activates both the GIP and GLP-1 receptors, two natural incretin hormones involved in blood sugar and appetite.
By targeting two hormone pathways instead of one, Mounjaro enhances insulin response, lowers fasting and after-meal glucose, slows digestion, and reduces appetite. It contains the same active ingredient as Zepbound®, though each brand has its own FDA-approved uses and dosing.
Most GLP-1 medications act on a single hormone. Mounjaro® is first-in-class because it activates two — GIP and GLP-1 — for a combined effect on blood sugar and appetite.
Tirzepatide activates both GIP and GLP-1 receptors — the first medication to do so — which is linked to its strong blood-sugar and appetite effects.
It boosts insulin release when glucose is high and lowers glucagon, improving fasting and after-meal blood sugar in a glucose-dependent way.
By slowing how quickly the stomach empties, it blunts post-meal glucose spikes and helps you feel full longer.
Both GIP and GLP-1 act on appetite centers in the brain, which is why many people eat less and lose weight while taking it.
Among GLP-1 medications for type 2 diabetes, tirzepatide stands out for its dual mechanism and its trial performance.
Mounjaro is the first and only single-molecule medication to activate both the GIP and GLP-1 receptors, a mechanism no other approved GLP-1 shares.
In head-to-head trials, tirzepatide lowered A1C more than semaglutide at every dose tested, helping many people reach blood-sugar goals.
A single weekly injection makes Mounjaro easy to fit into your routine, with a gradual dose schedule to ease your body in.
Mounjaro® is not FDA-approved for weight loss — that's its sibling Zepbound® (the same medicine, tirzepatide, approved for chronic weight management). Tell us your goals and our physicians will recommend the right option.
Mounjaro® starts low and increases about every four weeks so your body can adjust and side effects stay manageable. It's a once-weekly injection at every step.
The 2.5 mg starting dose helps your body adjust and isn't a maintenance dose. Your physician steps you up by 2.5 mg increments no sooner than every 4 weeks, based on your blood-sugar goals and tolerance — many people do well at 5 mg or 10 mg. The maximum dose is 15 mg once weekly. Always follow your prescriber's instructions.
Mounjaro® was studied in the SURPASS program in adults with type 2 diabetes. These are the headline, approved outcomes — individual results vary.
In the SURPASS trials, Mounjaro lowered A1C (a measure of long-term blood sugar) by an average of about 2% across doses — up to roughly 2.4% at the 10–15 mg doses — helping many adults with type 2 diabetes reach their targets alongside diet and exercise.
In a direct comparison (SURPASS-2), tirzepatide reduced A1C more than semaglutide 1 mg at every dose tested. Mounjaro also produced significant weight reductions as a secondary trial endpoint, though it is not approved for weight loss.
* Based on the SURPASS clinical program in adults with type 2 diabetes. Mounjaro® is not FDA-approved for weight loss. Individual results vary based on dose, adherence, and health history.
Same families, different molecules and approvals. Here's how Mounjaro® compares with the GLP-1 medications people most often ask about.
| Feature | Mounjaro® | Ozempic® | Zepbound® | Wegovy® |
|---|---|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide | Tirzepatide | Semaglutide |
| Drug class | GIP + GLP-1 dual | GLP-1 agonist | GIP + GLP-1 dual | GLP-1 agonist |
| Primary FDA use | Type 2 diabetes | Type 2 diabetes | Weight management | Weight management |
| Administration | Weekly injection | Weekly injection | Weekly injection | Weekly injection |
| Approved for weight loss | No (off-label) | No (off-label) | Yes | Yes |
| Brand maker | Eli Lilly | Novo Nordisk | Eli Lilly | Novo Nordisk |
Mounjaro® and Ozempic® are not FDA-approved for weight loss; Zepbound® and Wegovy® are. Your physician will recommend the most appropriate option for your diagnosis and goals.
Coverage for Mounjaro® is often strongest when it's prescribed for type 2 diabetes. Our care team helps you find the most affordable path.
A prescription is only part of the picture. Your program wraps the medication in ongoing clinical care and support to help you succeed.
If it's appropriate for you, your physician prescribes Mounjaro® at the right dose.
Secure telemedicine evaluations and follow-ups with licensed providers — no waiting rooms.
Guidance on titration and managing common side effects, with a team you can message.
Coordinators check coverage, apply savings programs, and lay out cash-pay options.
Track blood-sugar goals, doses, and milestones so you and your provider can see what's working.
Medication ships from a licensed pharmacy directly to your door, refilled on schedule.
Our telemedicine process is fast, private, and designed to take you from consultation to prescription as smoothly as possible.
Tell us about your medical history and health goals to see if you medically qualify — no cost, no obligation.
A licensed physician reviews your assessment, diagnosis, and goals via a secure telemedicine visit.
If Mounjaro® is appropriate, your physician issues your prescription and your starting dose.
Your medication ships from a licensed pharmacy to your door, with ongoing monthly clinical support included.
Eligibility is always determined by a licensed physician during your clinical evaluation. These are the general guidelines.
Take the free quiz and our care team will help you understand your options — including whether Mounjaro® or another medication is the right fit. No commitment required.
Medication works best as part of a routine. These habits support steady blood sugar, ease side effects, and build lasting health.
Consistent, balanced meals support smoother blood-sugar control and make GI side effects easier to manage.
Regular movement improves insulin sensitivity and complements the medication's blood-sugar benefits.
Plenty of water and fiber-rich foods help manage common digestive side effects like constipation.
Pick a consistent weekly injection day so the medication stays at steady levels and you don't miss doses.
Monitoring blood sugar (and weight, if relevant) helps you and your provider fine-tune your plan.
Ongoing check-ins keep you on track and make managing a chronic condition feel less isolating.
Most side effects are gastrointestinal and typically mild, most common at the start or after a dose increase, and improve as your body adjusts.
Most common at the start or after dose increases. Usually mild and eases within a few weeks. Smaller meals help.
Changes in digestion are common. Staying hydrated and keeping up fiber intake helps manage symptoms.
A common dual-agonist effect. Make sure you're still meeting your nutritional needs.
Bloating, fullness, or mild abdominal pain — especially after eating. Typically resolves as your body adjusts.
Low blood sugar risk rises if combined with insulin or sulfonylureas. Your physician may adjust those doses.
Mild redness or swelling at the site. Rotating injection sites helps. Resolves quickly in most cases.
Report severe upper-abdominal pain, fever, or jaundice promptly, as gallbladder problems can occur.
Very rare but serious. Stop the medication and contact your physician immediately if you have severe, persistent abdominal pain.
Important: Mounjaro® carries a boxed warning regarding the risk of thyroid C-cell tumors and should not be used by people with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2. It is not for use in type 1 diabetes. This is a general overview and not a complete list of side effects or warnings. Your physician will review your full health history and explain all relevant risks during your evaluation. Read full Important Safety Information →
A few simple practices keep your medication effective and your injections comfortable. Always follow the instructions that come with your pen.
Store Mounjaro® in the refrigerator. Do not freeze — discard any pen that has frozen. It can be kept at room temperature for a limited time per the label.
Inject into the abdomen, thigh, or upper arm, rotating the site each week, and inject on the same day weekly.
Take it within 4 days (96 hours) of the missed dose; if more time has passed, skip it. Don't double up — ask your provider.
Place used pens and needles in an FDA-cleared sharps container — never loose in household trash.
Use Mounjaro® the same day each week, at any time of day, with or without food, to keep levels steady.
Reach your care team about severe or persistent side effects, signs of an allergic reaction, or questions about your dose.
Fast Medical Weight Loss pairs FDA-approved medication with real clinical oversight and a process built around you.
Every prescription is evaluated and issued by a licensed provider — never an automated checkout.
Nationwide telemedicine access, with visits conducted by secure video or questionnaire.
Medication ships from licensed pharmacies straight to your door in plain packaging.
Your health information is protected at every step of your care.
Clear cash-pay rates plus insurance support — no surprise fees, cancel anytime.
A care team for dosing questions, side effects, and refills throughout your journey.
All-inclusive tirzepatide programs — licensed-physician visits and your medication included. No membership fees, cancel anytime. Multi-month plans save you more.
The 3-month and 6-month plans are billed once and are discounted versus the monthly rate. This offer cannot be combined with other discount codes or promotions. All medication requires a licensed-physician evaluation and prescription.
Clear answers to the most common questions about getting Mounjaro®, tirzepatide, and our telemedicine program.
No. Mounjaro® is FDA-approved for type 2 diabetes. Many people lose weight on it, but that use is off-label. The FDA-approved weight-loss form of tirzepatide is Zepbound®.
Mounjaro® is tirzepatide, a dual GIP and GLP-1 agonist. Ozempic® is semaglutide, a GLP-1 agonist. Both are once-weekly injections for type 2 diabetes; in the head-to-head SURPASS-2 trial, tirzepatide lowered A1C more than semaglutide at every dose.
Both contain the same active ingredient, tirzepatide, and are made by Eli Lilly. Mounjaro® is approved for type 2 diabetes, while Zepbound® is approved for chronic weight management.
Complete a short online medical questionnaire, have a telemedicine evaluation with a licensed physician, and if Mounjaro® is appropriate your prescription is issued and the medication ships to your door.
Mounjaro® starts at 2.5 mg once weekly for four weeks, then 5 mg, and can step up to 7.5, 10, 12.5, and a maximum of 15 mg weekly — at least four weeks at each dose, guided by your physician.
Our all-inclusive tirzepatide program starts at $399/month, including physician visits and medication, with discounted 3-month ($1,125) and 6-month ($2,199) plans. Insurance often covers Mounjaro® for type 2 diabetes.
The most common side effects are gastrointestinal — nausea, diarrhea, constipation, and decreased appetite — usually mild and temporary. Mounjaro® carries a boxed warning regarding the risk of thyroid C-cell tumors.
Evaluations are conducted via secure video or an asynchronous questionnaire, depending on your state and preference. All visits are HIPAA-compliant and conducted by licensed physicians.
Take the free quiz and let a licensed physician determine whether Mounjaro® — or another medication — is right for your diagnosis, goals, and budget.
Start My Free ConsultationMounjaro®, Zepbound®, and LillyDirect® are trademarks of Eli Lilly and Company; Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. This page has not been reviewed or endorsed by Eli Lilly or Novo Nordisk. Mounjaro® (tirzepatide) is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes. Mounjaro® is not FDA-approved for weight loss; tirzepatide is approved for chronic weight management under the brand name Zepbound®. *A1C reduction figures are from the SURPASS clinical program in adults with type 2 diabetes; individual results vary. ‡The $399/month program includes licensed-physician visits and a monthly medication supply, with no membership fees; cancel anytime. The 3-month and 6-month plans are billed once and are discounted versus the monthly rate; these offers cannot be combined with other discount codes or promotions. Pricing shown is illustrative and subject to change. Mounjaro® carries a boxed warning regarding the risk of thyroid C-cell tumors and is not for use in type 1 diabetes. This page is for informational purposes only and does not constitute medical advice. All treatment requires a licensed physician evaluation, eligibility, and a prescription; not all patients will qualify. Prescriptions require an online consultation with a healthcare provider who will determine whether a prescription is appropriate. Medication is dispensed through licensed pharmacies. ©2026 Fast Medical Weight Loss. HIPAA Compliant. All Rights Reserved.
©2026 All Rights Reserved. fastmedicalweightloss.org
